Oncolytics Biotech (ONC.TO, ONCY) on Friday said its fourth-quarter net loss doubled as the company advances towards registrational studies for its lead candidate pelareorep. A registration enabling trial is intended to generate sufficient data to file for a marketing application.
The net loss for the fourth quarter was $8.0 million, or $0.10 per share, compared with a loss of $3.9 million, or $0.05 per share, in the prior year period.
As at Dec. 31, Oncolytics reported $15.9 million in cash, giving it a projected cash runway through key milestones and into the third quarter of 2025.
Oncolytics is finalizing details for a large phase 2 study involving pelareorep in HR+/HER2- metastatic breast cancer, and expects a progression-free survival (PFS) readout two years after enrollment begins.
The final BRACELET-1 data showed robust improvements for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy in terms of PFS, Oncolytics said. If a PFS benefit comparable to the results seen in BRACELET-1 is observed in the registration-enabling study, Oncolytics will file for accelerated approval with the Food and Drug Administration.
Oncolytics was last seen unchanged in New York trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.